A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus placebo in subjects with relapsed/refractory indolent lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-5013-NHL-007

To Learn More Call
201-510-0910